Glenmark Pharmaceuticals

Glenmark delivered a strong Q3 FY26 with consolidated revenue of INR 3,960 croreCurrent reported value: INR 3,960 crore. No comparable prior figure is available in the source record., up 15.1% YoYCurrent 15.1% vs previous available quarter 76%., driven by broad-based growth across markets and currency tailwinds. India formulation grew 22.1% YoYCurrent 22.1% YoY. Reported change: +22.1% YoY., outperforming the IPM, while the US business (ex-outlicensing) grew 4.1%. EBITDA margin came in at 23%Current reported value: 23%. No comparable prior figure is available in the source record., in line with guidance. Management highlighted the ramp-up of innovative assets (RYALTRIS, TEVIMBRA, BRUKINSA) and the Monroe facility restart as key growth levers. Guidance for FY26 remains strong, with expectations of US respiratory approvals in Q4 and a net cash positive balance sheet. Risks include delayed US approvals and working capital normalization.